Urotech

Urotech, a South Korean biomedical firm established in 2019, is focused on advancing the diagnostic landscape for urological cancers. The company’s name is a blend of "Urology" and "Technology," reflecting its core mission to improve patient quality of life through technological solutions. Urotech operates in the in-vitro diagnostics market, specifically targeting bladder and prostate cancers with a non-invasive approach.

The company was founded by Wun Jae Kim, who also serves as its CEO. Urotech has developed diagnostic kits that analyze microRNA (miRNA) from urine samples to detect the presence of cancer. This method provides a significant advantage over more invasive and burdensome conventional diagnostic procedures, offering a simpler and more comfortable experience for patients. Its primary products are the mirBT Kit for bladder cancer and the mirCaP Kit for prostate cancer, which are based on cDNA synthesis and qPCR technology.

The business model encompasses both the development and sale of these diagnostic kits and the provision of genetic testing services. Hospitals and clinics can send urine samples to Urotech’s genetic testing center, where specialized personnel conduct the analysis, ensuring high accuracy. This dual approach caters to healthcare providers who may or may not have the in-house capabilities to perform the tests themselves. Located in Cheongju, South Korea, the company has established a network of clinical researchers and medical professionals to support its research and development efforts, which merge biotechnology, life sciences, and artificial intelligence.

Keywords: urology diagnostics, bladder cancer, prostate cancer, in-vitro diagnostics, miRNA analysis, non-invasive diagnostics, genetic testing services, liquid biopsy, molecular diagnostics, cancer screening, qPCR, cDNA synthesis, medical diagnostics, healthcare technology, South Korea biotech, Wun Jae Kim, Cheongju, urological oncology, diagnostic kits, urine-based testing